Skip to main content

Basilea receives grant for novel antibiotic

| News

Basilea receives grant for novel antibiotic

20.05.2021

The CARB-X initiative is granting a sum of 2.7 million US dollars to the Basel-based pharmaceuticals company Basilea. This will support development of an antibiotic from a novel active substance class. With its program, Basilea is fighting infections from resistant bacteria.

The public-private consortium CARB-X led by the University of Boston grants funding for the development of medicines to diagnose, prevent and treat drug-resistant bacteria. Now CARB-X has granted Basilea 2.7 million US dollars of funding according to a press release from the Basel-based pharmaceutical company. Basilea is already running a support program to develop an antibiotic from a novel active substance class to treat infections by drug-resistant, Gram-negative bacteria.

Laurenz Kellenberger, Chief Scientific Officer at Basilea, is quoted in the press release saying: “The medical problem of antimicrobial resistance keeps increasing.” The company develops drugs to treat cancer and infections. From summer 2022, it will be settled in the Switzerland Innovation Park Basel Area Main Campus in Allschwil in the canton of Basel-Landschaft. The new innovation campus is currently being built and upon completion will become the main campus of the Switzerland Innovation Park Basel Area run by Basel Area Business & Innovation. With the program being newly funded by CARB-X, Basilea is also pursuing a new approach.

As such, Basilea plans to develop an inhibitor for the DXR enzyme. This enzyme is needed by some Gram-negative bacteria that the World Health Organisation has classed as dangerous “priority pathogens”. Kellenberger adds: “We are delighted to be partnering with CARB-X for the development of truly innovative antibiotics directed against this unexploited bacterial target. Basilea remains committed to leverage its proven ability in the discovery, development and commercialization of novel anti-infectives to deliver new treatment options to patients facing bacterial drug-resistance worldwide.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Do you have a question? We'd like to hear from you.